502.373.0258 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia

0 studies enrolling now · 1 studies all time

What they study most

Cardiovascular Diseases

Studies at this site

• Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. — Completed